COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Turkish Acquired Haemophilia Registry (EHEM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01403740
Recruitment Status : Unknown
Verified June 2011 by Turkish Society of Hematology.
Recruitment status was:  Not yet recruiting
First Posted : July 27, 2011
Last Update Posted : July 27, 2011
Information provided by:
Turkish Society of Hematology

Brief Summary:
Turkish Acquired Haemophilia Registry is a database in which information about clinical features and therapeutic management of acquired haemophilia is collected in Turkey.This is a multicentre, retrospective and prospective registry of subjects diagnosed and/or treated for acquired haemophilia. Patients will be registered and the response to different therapies, details of each bleeding episode and the outcome of haemostatic and immunosuppressive therapy (IST) will be recorded. Any male or female subject diagnosed with inhibitors to FVIII or other factors and treated for acquired haemophilia can be entered on the registry. Patients will be treated according to local practice. No additional tests or procedures are required by the registry. The retrospective period will not be time-limited and data will be collected from those recorded in the hospital notes. The prospective period will begin in September 1.2011, and will last for two years.

Condition or disease Intervention/treatment
Acquired Haemophilia Drug: rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin

Layout table for study information
Study Type : Observational
Estimated Enrollment : 250 participants
Official Title: Observational Acquired Haemophilia Registry
Study Start Date : September 2011
Estimated Primary Completion Date : August 2013
Estimated Study Completion Date : August 2013

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Acquired haemophilia patients Drug: rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin
According to local clinical standards

Biospecimen Retention:   Samples Without DNA
Blood sample for coagulation factor determination

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with acquired haemophilia diagnosed and/or treated in haematology clinics

Inclusion Criteria:

  • Acquired haemophilia diagnosis, written consent

Exclusion Criteria:

  • Being unable to give written consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01403740

Layout table for location contacts
Contact: Dilek Solakoglu, MD 902123253232
Contact: Volkan Aydin, MD 902123253232

Layout table for location information
Trakya University Haematology Clinic
Edirne, Turkey, 22030
Contact: Muzaffer A Demir, Prof    902842351041   
Contact: Dilek Solakoglu, MD    902123253232   
Principal Investigator: Muzaffer A Demir, Prof         
Sponsors and Collaborators
Turkish Society of Hematology
Layout table for investigator information
Principal Investigator: Muzaffer A Demir, Prof THD
Layout table for additonal information
Responsible Party: Turkish Society of Hematology Identifier: NCT01403740    
Other Study ID Numbers: 2011/HEM/001
First Posted: July 27, 2011    Key Record Dates
Last Update Posted: July 27, 2011
Last Verified: June 2011
Keywords provided by Turkish Society of Hematology:
acquired haemophilia
factor VIII
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Calcineurin Inhibitors
Antimetabolites, Antineoplastic